1809249-37-3 exporter Hot sale in China
Remdesivir (Remdesivir) is a nucleoside analog and is an inhibitor of RNA-dependent RNA polymerase (RdRp), which can inhibit viral nucleic acid synthesis and anti-virus. The current clinical Chemicalbook bed study for Ebola virus infection is in phase II. MERS-infected mice performed much better after receiving this combination therapy, with reduced virus replication and improved lung function. Recent studies have shown that Remdesivir has a certain active effect on inhibiting the new coronavirus.
Biological activity
Remdesivir (GS-5734) is a nucleoside analog with antiviral activity. In HAE cells, the EC50 value of SARSChemicalbook-CoV and MERS-CoV is 74nM. In delayed brain tumor cells, it has antiviral activity.
The EC50 value is 30 nM.
Application status
Remdesivir is a nucleotide analog prodrug. In vitro experiments and animal model data indicate that Redecive inhibits SARS (SARS coronavirus) and Middle East respiratory syndrome (MERS coronavirus) by inhibiting RNA-derived RNA polymerase (RdRp). , Chemicalbook Ebola coronavirus and many other coronaviruses. In vitro cell experiments show that the median effective concentration (IC50) of Radixivir against the new coronavirus is 0.77μmol·L-1. However, Remdesivir has not been approved for marketing in any country, and its effectiveness and safety have not been confirmed by phase III clinical trials, and only phase II clinical trials have been carried out for Ebola virus.
Product advantage introduction:
Remdesivir is a nucleoside analogue being researched by Gilead Sciences. On May 7, 2020, the Japanese government approved Gilead Sciences (GILD.US) drug Remdesivir for the treatment of new crowns Viral drugs have become the country's first officially approved drug for the treatment of new coronavirus-related diseases, and priority is given to severely ill patients.
Remdesivir has not been licensed or approved in countries other than Japan. In May 2020, Remdesivir was authorized by the U.S. Food and Drug Administration (FDA) with an emergency use authorization (EUA). Although it has not been officially approved by the FDA, its Chemicalbook has a very broad market prospect and has certain strategic drug value. Remdesivir has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in in vitro and in vivo studies in animal models, including Ebola virus, Marburg virus, and Middle East respiratory syndrome (MERS
) And atypical pneumonia (SARS) viruses, so remdesivir may play a therapeutic role in epidemics caused by similar viruses in the future. At present, Remdesivir has been approved for use in various forms in 41 countries and regions including the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India and Canada.
|
|
|
|
Product name |
Remdesivir |
|
Cas number |
1809249-37-3 |
|
Molecular formula |
C27H35N6O8P |
|
Molecular weight |
602.58 |
|
Appearance |
White solid powder |
|
Loss on drying |
0.5% |
|
Residue in ignition |
≤0.1% |
|
Individuel impurity |
≤0.1% |
|
Total impurities |
≤1.0% |
|
Specific Rotation |
-19°~ -22° |
|
Assay |
98.0%~101.0% |
Company Information
Product advantage introduction:
Remdesivir is a nucleoside analogue being researched by Gilead Sciences. On May 7, 2020, the Japanese government approved Gilead Sciences (GILD.US) drug Remdesivir for the treatment of new crowns Viral drugs have become the country's first officially approved drug for the treatment of new coronavirus-related diseases, and priority is given to severely ill patients.
Remdesivir has not been licensed or approved in countries other than Japan. In May 2020, Remdesivir was authorized by the U.S. Food and Drug Administration (FDA) with an emergency use authorization (EUA). Although it has not been officially approved by the FDA, its Chemicalbook has a very broad market prospect and has certain strategic drug value. Remdesivir has broad-spectrum antiviral activity. It has shown its effect on a variety of emerging viral pathogens in in vitro and in vivo studies in animal models, including Ebola virus, Marburg virus, and Middle East respiratory syndrome (MERS
) And atypical pneumonia (SARS) viruses, so remdesivir may play a therapeutic role in epidemics caused by similar viruses in the future. At present, Remdesivir has been approved for use in various forms in 41 countries and regions including the United States, Japan, the United Kingdom, the European Union, the United Arab Emirates, India and Canada.
